---
document_datetime: 2025-12-02 05:01:59
document_pages: 1
document_pathfilename: www.ema.europa.eu/en/medicines/human/EPAR/encyzix.html
document_name: encyzix.html
version: success
processing_time: 0.0652547
conversion_datetime: 2025-12-27 22:33:06.033653
docling_version:
  docling-serve: 1.9.0
  docling-jobkit: 1.8.0
  docling: 2.66.0
  docling-core: 2.57.0
  docling-ibm-models: 3.10.3
  docling-parse: 4.7.2
  python: cpython-313 (3.13.11)
  plaform: macOS-26.2-arm64-arm-64bit-Mach-O
---
# EnCyzix

[RSS](/en/individual-human-medicine.xml/66021)

##### Refused

This medicine has been refused authorisation

enclomifene Medicine Human Refused

Page contents

## Page contents

- [Overview](#overview)
- [Product details](#product-details)
- [Application details](#authorisation-details)
- [Assessment history](#assessment-history)
- [News on EnCyzix](#news-on)

- Application under evaluation
- CHMP opinion
- European Commission decision

## Overview

On 25 January 2018, the Committee for Medicinal Products for Human Use (CHMP) adopted a negative opinion, recommending the refusal of the marketing authorisation for the medicinal product EnCyzix, intended for the treatment of hypogonadotropic hypogonadism in men.

The company that applied for authorisation is Renable Pharma Limited. It may request a re-examination of the opinion within 15 days of receipt of notification of this negative opinion.

Expand section

Collapse section

## What is EnCyzix?

EnCyzix is a medicine that contains the active substance enclomifene. It was to be available as capsules to be taken by mouth.

## What was EnCyzix expected to be used for?

EnCyzix was expected to be used to treat hypogonadotropic hypogonadism in men. In this condition, the sex organs (the testes in men) do not work properly resulting in symptoms such as infertility, low libido, impotence, weakened bones and weight gain. EnCyzix was to be used in overweight men with a body mass index (BMI) of at least 25 kg/m 2 .

## How does EnCyzix work?

Overweight men with hypogonadotropic hypogonadism produce too much of the hormone oestrogen. This stops the release of other hormones called gonadotrophins, which are needed for the testes to produce testosterone and to work normally. EnCyzix blocks the excess oestrogen enabling release of gonadotrophins and normal testicular function.

## What did the company present to support its application?

The company presented the results of 4 main studies involving a total of 588 patients. Patients were given either EnCyzix, or placebo (a dummy treatment) with and without application of a testosterone gel. The main measures of effectiveness were the amount of sperm produced and testosterone levels.

## What were the CHMP's main concerns that led to the refusal?

The CHMP noted that although the studies showed an increase in testosterone levels with EnCyzix, they did not look at whether EnCyzix would improve symptoms such as bone strength, weight gain, impotence and libido. In addition, there is a risk of venous thromboembolism (problems due to the formation of blood clots in the veins) with the medicine. Therefore, the CHMP was of the opinion that the benefits of EnCyzix did not outweigh its risks and recommended that it be refused marketing authorisation.

## What consequences does this refusal have for patients in clinical trials or compassionate use programmes?

The company informed the CHMP that there are no ongoing clinical trials or compassionate use programmes with EnCyzix.

Questions and answers on refusal of the marketing authorisation for EnCyzix (enclomifene)

Adopted

Reference Number: EMA/CHMP/54473/2018

English (EN) (72.65 KB - PDF)

**First published:** 26/01/2018

**Last updated:** 20/04/2018

[View](/en/documents/smop-initial/questions-and-answers-refusal-marketing-authorisation-encyzix-enclomifene_en.pdf)

[Other languages (22)](#file-language-dropdown-553)

български (BG) (103.11 KB - PDF)

**First published:**

26/01/2018

**Last updated:**

20/04/2018

[View](/bg/documents/smop-initial/questions-and-answers-refusal-marketing-authorisation-encyzix-enclomifene_bg.pdf)

español (ES) (71.24 KB - PDF)

**First published:**

26/01/2018

**Last updated:**

20/04/2018

[View](/es/documents/smop-initial/questions-and-answers-refusal-marketing-authorisation-encyzix-enclomifene_es.pdf)

čeština (CS) (93.91 KB - PDF)

**First published:**

26/01/2018

**Last updated:**

20/04/2018

[View](/cs/documents/smop-initial/questions-and-answers-refusal-marketing-authorisation-encyzix-enclomifene_cs.pdf)

dansk (DA) (70.78 KB - PDF)

**First published:**

26/01/2018

**Last updated:**

20/04/2018

[View](/da/documents/smop-initial/questions-and-answers-refusal-marketing-authorisation-encyzix-enclomifene_da.pdf)

Deutsch (DE) (71.87 KB - PDF)

**First published:**

26/01/2018

**Last updated:**

20/04/2018

[View](/de/documents/smop-initial/questions-and-answers-refusal-marketing-authorisation-encyzix-enclomifene_de.pdf)

eesti keel (ET) (70.57 KB - PDF)

**First published:**

26/01/2018

**Last updated:**

20/04/2018

[View](/et/documents/smop-initial/questions-and-answers-refusal-marketing-authorisation-encyzix-enclomifene_et.pdf)

ελληνικά (EL) (98.58 KB - PDF)

**First published:**

26/01/2018

**Last updated:**

20/04/2018

[View](/el/documents/smop-initial/questions-and-answers-refusal-marketing-authorisation-encyzix-enclomifene_el.pdf)

français (FR) (71.62 KB - PDF)

**First published:**

26/01/2018

**Last updated:**

20/04/2018

[View](/fr/documents/smop-initial/questions-and-answers-refusal-marketing-authorisation-encyzix-enclomifene_fr.pdf)

hrvatski (HR) (88.87 KB - PDF)

**First published:**

26/01/2018

**Last updated:**

20/04/2018

[View](/hr/documents/smop-initial/questions-and-answers-refusal-marketing-authorisation-encyzix-enclomifene_hr.pdf)

italiano (IT) (71.03 KB - PDF)

**First published:**

26/01/2018

**Last updated:**

20/04/2018

[View](/it/documents/smop-initial/questions-and-answers-refusal-marketing-authorisation-encyzix-enclomifene_it.pdf)

latviešu valoda (LV) (98 KB - PDF)

**First published:**

26/01/2018

**Last updated:**

20/04/2018

[View](/lv/documents/smop-initial/questions-and-answers-refusal-marketing-authorisation-encyzix-enclomifene_lv.pdf)

lietuvių kalba (LT) (93.47 KB - PDF)

**First published:**

26/01/2018

**Last updated:**

20/04/2018

[View](/lt/documents/smop-initial/questions-and-answers-refusal-marketing-authorisation-encyzix-enclomifene_lt.pdf)

magyar (HU) (89.44 KB - PDF)

**First published:**

26/01/2018

**Last updated:**

20/04/2018

[View](/hu/documents/smop-initial/questions-and-answers-refusal-marketing-authorisation-encyzix-enclomifene_hu.pdf)

Malti (MT) (93.34 KB - PDF)

**First published:**

26/01/2018

**Last updated:**

20/04/2018

[View](/mt/documents/smop-initial/questions-and-answers-refusal-marketing-authorisation-encyzix-enclomifene_mt.pdf)

Nederlands (NL) (71.17 KB - PDF)

**First published:**

26/01/2018

**Last updated:**

20/04/2018

[View](/nl/documents/smop-initial/questions-and-answers-refusal-marketing-authorisation-encyzix-enclomifene_nl.pdf)

polski (PL) (93.81 KB - PDF)

**First published:**

26/01/2018

**Last updated:**

20/04/2018

[View](/pl/documents/smop-initial/questions-and-answers-refusal-marketing-authorisation-encyzix-enclomifene_pl.pdf)

português (PT) (71.38 KB - PDF)

**First published:**

26/01/2018

**Last updated:**

20/04/2018

[View](/pt/documents/smop-initial/questions-and-answers-refusal-marketing-authorisation-encyzix-enclomifene_pt.pdf)

română (RO) (89.66 KB - PDF)

**First published:**

26/01/2018

**Last updated:**

20/04/2018

[View](/ro/documents/smop-initial/questions-and-answers-refusal-marketing-authorisation-encyzix-enclomifene_ro.pdf)

slovenčina (SK) (91.77 KB - PDF)

**First published:**

26/01/2018

**Last updated:**

20/04/2018

[View](/sk/documents/smop-initial/questions-and-answers-refusal-marketing-authorisation-encyzix-enclomifene_sk.pdf)

slovenščina (SL) (90.04 KB - PDF)

**First published:**

26/01/2018

**Last updated:**

20/04/2018

[View](/sl/documents/smop-initial/questions-and-answers-refusal-marketing-authorisation-encyzix-enclomifene_sl.pdf)

Suomi (FI) (70.48 KB - PDF)

**First published:**

26/01/2018

**Last updated:**

20/04/2018

[View](/fi/documents/smop-initial/questions-and-answers-refusal-marketing-authorisation-encyzix-enclomifene_fi.pdf)

svenska (SV) (70.77 KB - PDF)

**First published:**

26/01/2018

**Last updated:**

20/04/2018

[View](/sv/documents/smop-initial/questions-and-answers-refusal-marketing-authorisation-encyzix-enclomifene_sv.pdf)

## Product details

Name of medicine EnCyzix Active substance enclomifene citrate International non-proprietary name (INN) or common name enclomifene Therapeutic area (MeSH) Hypogonadism Anatomical therapeutic chemical (ATC) code G03X

### Pharmacotherapeutic group

Sex hormones and modulators of the genital system

## Application details

EMA product number EMEA/H/C/004198 Marketing authorisation applicant Renable Pharma Limited Opinion adopted 25/01/2018 Refusal of marketing authorisation 06/04/2018

## Assessment history

EnCyzix : EPAR - Public assessment report

Adopted

Reference Number: EMA/88321/2018

English (EN) (4.37 MB - PDF)

**First published:** 20/04/2018

**Last updated:** 20/04/2018

[View](/en/documents/assessment-report/encyzix-epar-public-assessment-report_en.pdf)

#### News on EnCyzix

[Meeting highlights from the Committee for Medicinal Products for Human Use (CHMP) 22-25 January 2018](/en/news/meeting-highlights-committee-medicinal-products-human-use-chmp-22-25-january-2018) 26/01/2018

**This page was last updated on** 26/01/2018

## Share this page

[Back to top](#main-content)